Neuromyelitis Optica Clinical Trial
Official title:
Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2 years. Dosage was adjusted according to side effects. Neurological assessment including the determination of the Expanded Disability Status Scale (EDSS) score and ophthalmologic evaluations were performed every 3 months and during relapses. Flow cytometric analysis, brain and spinal cord MRI was performed at baseline, 6, 12, 18, and 24 months.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02283671 -
Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B
|
Phase 1 | |
| Recruiting |
NCT01024985 -
Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct
|
N/A | |
| Recruiting |
NCT04601142 -
Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gene Polymorphism
|
||
| Completed |
NCT03942952 -
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
|
||
| Recruiting |
NCT05573711 -
Restless Legs Syndrome in People With Neuromyelitis Optica Spectrum Disorder
|
||
| Not yet recruiting |
NCT06118398 -
Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
|
||
| Recruiting |
NCT05566769 -
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
|
N/A | |
| Withdrawn |
NCT03829566 -
Autologous Transplant To End NMO Spectrum Disorder
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05403138 -
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
| Completed |
NCT03350633 -
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05356858 -
An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients
|
Phase 2 | |
| Recruiting |
NCT05982925 -
Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
|
||
| Active, not recruiting |
NCT00445367 -
Biobank For MS And Other Demyelinating Diseases
|
||
| Terminated |
NCT02398994 -
A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis
|
Phase 3 | |
| Withdrawn |
NCT02087813 -
Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses
|
Phase 1 | |
| Terminated |
NCT01339455 -
Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04614454 -
High Frequency Impulse Therapy for Neuropathic Pain in NMOSD
|
Phase 2 | |
| Recruiting |
NCT03370965 -
Optic Neuritis Differential Diagnosis Study
|
N/A | |
| Completed |
NCT01777412 -
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
|
Phase 1 | |
| Recruiting |
NCT01623076 -
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
|